SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-22-004706
Filing Date
2022-02-15
Accepted
2022-02-15 17:25:13
Documents
12
Period of Report
2022-02-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 43095
  Complete submission text file 0001493152-22-004706.txt   211463

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE otlc-20220209.xsd EX-101.SCH 3036
3 XBRL LABEL FILE otlc-20220209_lab.xml EX-101.LAB 34476
4 XBRL PRESENTATION FILE otlc-20220209_pre.xml EX-101.PRE 22597
6 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3293
Mailing Address 29397 AGOURA RD. #107 AGUORA HILLS CA 91301
Business Address 29397 AGOURA RD. #107 AGUORA HILLS CA 91301 650-635-7000
Oncotelic Therapeutics, Inc. (Filer) CIK: 0000908259 (see all company filings)

IRS No.: 133679168 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21990 | Film No.: 22640308
SIC: 2834 Pharmaceutical Preparations